



Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

J. Cassinello¹ · J. Á. Arranz² · J. M. Piulats³ · A. Sánchez⁴ · B. Pérez-Valderrama⁵ · B. Mellado⁶ · M. Á. Climent⁷ · D. Olmos⁸ · J. Carles⁹ · M. Lázaro¹⁰

Published online: 5 January 2018
© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Correction to: Clin Transl Oncol
<https://doi.org/10.1007/s12094-017-1783-2>

The original article shows two mistakes, which are listed here:

1. In paragraph 6 of the section “Second-line therapy: cabazitaxel and second-line hormone therapy” there was a mistake in line 6; instead of 0.65, it should have been written 0.74:

Overall survival was longer in the abiraterone group (14.8 months vs. 10.9 months; hazard ratio, 0.74; $p < 0.001$).

2. In the original version of this article two algorithms were referenced in section “Methodology”, but were not included in the article. The missing algorithms are listed here:

The original article can be found online at <https://doi.org/10.1007/s12094-017-1783-2>.

✉ J. Cassinello
jcassinelloespinosa@gmail.com

¹ Medical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain

² Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain

³ Medical Oncology Department, Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, Spain

⁴ Medical Oncology Department, Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Spain

⁵ Medical Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain

⁶ Medical Oncology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain


⁷ Medical Oncology Department, Fundacion Instituto Valenciano de Oncología, Valencia, Spain

⁸ CNIO-IBIMA Genito-Urinary Cancer Unit, Medical Oncology Department, Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, Spain

⁹ Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain

¹⁰ Medical Oncology Department, Hospital Universitario de Vigo, Vigo, Spain

Algorithm 1: Castration resistant disease



Algorithm 2: Hormonosensitive disease

